Immunohistochemical Analysis of Prostate Apoptosis Response-4 (Par-4) in Mexican Women with Breast Cancer: A Preliminary Study

Archives of Medical Research

Volumn 41, Issue 4, 2010, Pages 261-268

  Méndez López, Luis Fernando ^a   Zapata Benavides, Pablo ^a   Zavala Pompa, Angel ^b   Aguado Barrera, Miguel Elías ^a   Pacheco Calleros, Javier ^b   Rodríguez Padilla, Cristina ^a   Cerda Flores, Ricardo Martín ^b   Cortés Gutiérrez, Elva Irene ^a   Dávila Rodríguez, Martha Imelda ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Breast cancer; Immunohistochemistry; Par 4

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 4; APOPTOSIS REGULATORY PROTEIN; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER TISSUE; COMPUTER PROGRAM; CONTROL GROUP; EPITHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MEXICO; MYOEPITHELIUM; PROGNOSIS; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STAINING; STROMA; SURVIVAL; BREAST DISEASE; BREAST TUMOR; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; APOPTOSIS REGULATORY PROTEINS; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEXICO; MIDDLE AGED; YOUNG ADULT;

EID: 77954640885     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2010.05.005     Document Type: Article

References (43)

1. Sells S.F., Wood D.P., Joshi-Barve S.S., et al. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994, 5:457-466.
2. Sells S.F., Han S.S., Muthukkumar S., et al. Expression and function of the leucine zipper protein par-4 in apoptosis. Mol Cell Biol 1997, 17:3823-3832.
3. El-Guendy N., Rangnekar V.M. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 2003, 283:51-66.
4. Gurumurthy S., Goswami A., Vasudevan K.M., et al. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005, 25:1146-1161.
5. Chakraborty M., Qiu S.G., Vasudevan K., et al. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001, 61:7255-7263.
6. Garcia-Cao I., Duran A., Collado M., et al. Tumour suppression activity of the proapoptotic regulator Par4. EMBO Rep 2005, 6:577-583.
7. Moreno-Bueno G., Fernandez-Marcos P.J., Collado M., et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007, 67:1927-1934.
8. Cook J., Krishnan S., Ananth S., et al. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 1999, 18:1205-1208.
9. Goswami A., Burikhanov R., de Thonel A., et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 2005, 20:33-44.
10. Zapata-Benavides P., Méndez-Vázquez J.L., González-Rocha T.R., et al. Expression of prostate apoptosis response (par-4) is associated with progesterone receptor in breast cancer. Arch Med Res 2009, 40:595-599.
11. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics 2000. CA Cancer J Clin 2000, 50:7-33.
12. Beckmann M.W., Niederacher D., Schnurch H.G., et al. Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Mol Med 1997, 75:429-439.
13. Haybittle J.L., Blamey R.W., Elston C.W., et al. A prognostic index in primary breast cancer. Br J Cancer 1982, 45:361-366.
14. Galea M.H., Blamey R.W., Elston C.E., et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
15. Tavassoli F.A., Devilee P. World Health Organization classification of tumors. Pathology and genetics of tumors of the breast and female genital organs 2003, IARC Press, Lyon, France.
16. McDonald J.W., Pilgram T.K. Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma. Histopathology 1999, 34:439-446.
17. Estrada C.R., Adam R.M., Eaton S.H., et al. Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder. Lab Invest 2006, 86:1293-1302.
18. Boghaert E.R., Sells S.F., Walid A.J., et al. Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 1997, 8:881-890.
19. Streuli C.H., Haslam S.Z. Control of mammary gland development and neoplasia by stromal-epithelial interactions and extracellular matrix. J Mamm Gland Biol Neoplasia 1998, 3:107-108.
20. Vogel P.M., Georgiade N.G., Fetter B.F. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981, 104:23-34.
21. Clark G.M., McGuire W.L. New biologic prognostic factors in breast cancer. Oncology 1999, 23:49-54.
22. Burikhanov R., Zhao Y., Goswami A., et al. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009, 138:377-388.
23. El-Guendy N., Zhao Y., Gurumurthy S., et al. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 2003, 23:5516-5525.
24. Elledge R.M., Allred D.C. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994, 32:39-47.
25. Goswami A., Burikhanov R., de Thonel A., et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 2005, 20:33-44.
26. Li M., Hu J., Heermeier K., et al. Apoptosis and remodeling of mammary gland tissue during involution proceed through p53-independent pathways. Cell Growth Differ 1996, 7:13-20.
27. Shilkaitis A., Graves J., Mehta R.R., et al. Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis. Cell Growth Differ 2000, 11:437-445.
28. Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80:879-886.
29. Yang T., Buchan H.L., Townsend K.J., et al. MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 1996, 166:523-536.
30. Thomas A., Rouby S., Reed J.C., et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996, 12:1055-1062.
31. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000, 19:6627-6631.
32. Cheema S.K., Mishra S.K., Rangnekar V.M., et al. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003, 278:19995-20005.
33. Qiu G., Ahmed M., Sells S.F., et al. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1999, 18:623-631.
34. Bieberich E., MacKinnon S., Silva J., et al. Regulation of cell death in mitotic neural progenitor cells by asymmetric distribution of prostate apoptosis response 4 (PAR-4) and simultaneous elevation of endogenous ceramide. J Cell Biol 2003, 162:469-479.
35. Kögel D., Plöttner O., Landsberg G., et al. Cloning and characterization of Dlk, a novel serine/threonine kinase that is tightly associated with chromatin and phosphorylates core histones. Oncogene 1998, 19(17):2645-2654.
36. Diaz-Meco M.T., Lallena M.J., Monjas A., et al. Inactivation of the inhibitory κB protein kinase/nuclear factor κB pathway by Par-4 expression potentiates tumor necrosis factor α induced apoptosis. J Biol Chem 1999, 274:19606-19612.
37. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6910-6924.
38. Stambolic V., Mak T.W., Woodgett J.R. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 1999, 18:6094-6103.
39. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2002, 100:57-70.
40. Denmeade S.R., Isaacs J.T. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 1996, 35:281-306.
41. Ahmed M.M., Sheldon D., Fruitwala M.A., et al. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer 2008, 122:63-70.
42. Boehrer S., Chow K.U., Puccetti E., et al. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2001, 2:103-107.
43. Faratian D., Barlett J. Predictive markers in breast cancer-the future. Histopathology 2008, 52:91-98.